OBJECTIVES: The present paper aims to investigate the effect of psoriatic arthritis (PsA) disease duration on the outcome of treatment with etanercept (ETN) in patients with PsA who also have moderate-to-severe psoriasis. METHODS: Patients from the PRESTA trial who received ≥1 ETN 50 mg once weekly (QW) dose and had ≥1 post-baseline value were evaluated. Baseline and after-treatment changes were compared between patients with PsA ≤2 years versus PsA >2 years in efficacy measures (physician global assessment [PGA] arthritis, swollen joint count and Psoriasis Area and Severity Index [PASI]) and patient reported outcomes (PROs; joint pain, arthritis activity, Euro-Qol [EQ-5D] utility and visual analogue score [VAS]) using linear regression analysis. RESULTS:Baseline efficacy measures were similar between the PsA ≤2 years (n=103) and PsA >2 years (n=269) groups, with the exception of PGA arthritis (p=0.006). At week 24, improvements in efficacy measures were observed in both groups but were significantly greater for PGA arthritis in the PsA ≤2 years group (p=0.03). Quality of life (QoL), measured using PROs, was generally lower at baseline in patients with PsA >2 years. Clinically meaningful improvements were seen in QoL with ETN treatment in both groups, but the change from baseline scores at week 24 were significantly higher in PsA ≤2 years group for joint pain (p=0.007), arthritis activity (p=0.01), EQ-5D utility (p=0.046) and EQ-5D VAS (p=0.04) responses. CONCLUSIONS: PsA patients responded to ETN 50 mg QW treatment irrespective of disease duration; however, patients with shorter PsA duration had greater improvements in arthritis scores and several PRO measures.
RCT Entities:
OBJECTIVES: The present paper aims to investigate the effect of psoriatic arthritis (PsA) disease duration on the outcome of treatment with etanercept (ETN) in patients with PsA who also have moderate-to-severe psoriasis. METHODS:Patients from the PRESTA trial who received ≥1 ETN 50 mg once weekly (QW) dose and had ≥1 post-baseline value were evaluated. Baseline and after-treatment changes were compared between patients with PsA ≤2 years versus PsA >2 years in efficacy measures (physician global assessment [PGA] arthritis, swollen joint count and Psoriasis Area and Severity Index [PASI]) and patient reported outcomes (PROs; joint pain, arthritis activity, Euro-Qol [EQ-5D] utility and visual analogue score [VAS]) using linear regression analysis. RESULTS: Baseline efficacy measures were similar between the PsA ≤2 years (n=103) and PsA >2 years (n=269) groups, with the exception of PGAarthritis (p=0.006). At week 24, improvements in efficacy measures were observed in both groups but were significantly greater for PGAarthritis in the PsA ≤2 years group (p=0.03). Quality of life (QoL), measured using PROs, was generally lower at baseline in patients with PsA >2 years. Clinically meaningful improvements were seen in QoL with ETN treatment in both groups, but the change from baseline scores at week 24 were significantly higher in PsA ≤2 years group for joint pain (p=0.007), arthritis activity (p=0.01), EQ-5D utility (p=0.046) and EQ-5D VAS (p=0.04) responses. CONCLUSIONS: PsA patients responded to ETN 50 mg QW treatment irrespective of disease duration; however, patients with shorter PsA duration had greater improvements in arthritis scores and several PRO measures.
Authors: Tatiana Cobo-Ibáñez; Virginia Villaverde; Daniel Seoane-Mato; Santiago Muñoz-Fernández; Mercedes Guerra; Petra Díaz Del Campo; Juan D Cañete Journal: Rheumatol Int Date: 2015-10-05 Impact factor: 2.631
Authors: Ennio Lubrano; Andrea Delle Sedie; Marco Romanelli; Maria Sole Chimenti; Luca Bianchi; Stefano Piaserico; Catia De Felice; Dario Graceffa; Maria Ilenia De Andres; Salvatore Curatolo; Rosa Daniela Grembiale; Stefano Dastoli; Chiara Arcuri; Rosa Giuseppa Angileri; Francesca Prignano; Francesca Bandinelli; Elena Baldissera; Santo Raffaele Mercuri; Chiara Franchi; Matteo Longhi; Angela Patrì; Francesco Caso; Giuseppe Passiu; Maria Antonia Montesu; Simone Parisi; Elena Stroppiana; Genoveffa Scotto di Luzio; Giovanni Italiano; Sergio Di Nuzzo; Daniele Santilli; Laura Bigi; Federica Lumetti; Concetto Paolo Agnusdei; Maria Grazia Ferrucci; Giuliana Gualberti; Francesca Marando; Roberta Ramonda; Francesco Cusano Journal: Clin Rheumatol Date: 2020-11-06 Impact factor: 2.980